Home › Leucemia linfatica cronica › Pennsylvania › Philadelphia
Studi clinici su Leucemia linfatica cronica a Philadelphia, PA
11 studi su Leucemia linfatica cronica cercano partecipanti presso sedi a Philadelphia e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
In reclutamentoFase 3
- Thomas Jefferson University Hospital, Philadelphia
- Jefferson Torresdale Hospital, Philadelphia
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
In reclutamentoStudio osservazionaleVolontari sani benvenuti
- Reading Hospital McGlinn Cancer Institute at Phoenixville, Phoenixville · a 22 mi di distanza
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
In reclutamentoFase 3
- Thomas Jefferson University Hospital, Philadelphia
- Jefferson Torresdale Hospital, Philadelphia
- Asplundh Cancer Pavilion, Willow Grove · a 13 mi di distanza
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
In reclutamentoFase 3
- Thomas Jefferson University, Philadelphia
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
In reclutamentoFase 3
- Fox Chase Cancer Center, Philadelphia
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
In reclutamentoFase 3
- Consultants in Medical Oncology and Hematology (CMOH) ( Site 8002), Broomall · a 10 mi di distanza
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
In reclutamentoFase 1/2
- Research Site, Philadelphia
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
In reclutamentoFase 1
- University of Pennsylvania, Abramson Cancer Center, Philadelphia
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
In reclutamentoFase 4
- University of Pennsylvania Hospital, Philadelphia
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
In reclutamentoFase 4
- University of Pennsylvania Hospital, Philadelphia
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
In reclutamentoFase 2
- Pennsylvania Oncology Hematolo /ID# 249637, Philadelphia
Studi su Leucemia linfatica cronica in altre città
- Boston, MA31 studi
- Columbus, OH28 studi
- Durham, NC27 studi
- Washington, DC22 studi
- Seattle, WA20 studi
- Rochester, MN19 studi
- New York City, NY18 studi
- Houston, TX17 studi
- Baldwin Park, CA16 studi
- Milwaukee, WI15 studi
- Chicago, IL14 studi
- Cincinnati, OH14 studi
Altri studi a Philadelphia
- Cancro (tutti i tipi)59 studi
- Cancro al seno56 studi
- Cancro del polmone non a piccole cellule51 studi
- Cancro metastatico46 studi
- Cancro colorettale44 studi
- Cancro ovarico44 studi
- Cancro alla prostata44 studi
- Cancro ai polmoni36 studi
- Leucemia mieloide acuta34 studi
- Insufficienza cardiaca31 studi
- Cancro dell'endometrio28 studi
- Depressione26 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.